Appl. No. 09/998,966 Amdt. dated March 1, 2004 Reply to Final Office action of October 30, 2003 Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Previously Amended) An isolated nucleic acid comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 2 or the complement of said nucleic acid sequence.
- 2. (Currently Amended) The nucleic acid of claim 1, wherein said nucleic acid is selected from the group consisting of DNA or and RNA.
- 3. (Currently Amended) An isolated nucleic acid comprising <u>a nucleic acid sequence an open reading frame</u> that encodes a mature polypeptide of SEQ ID NO: 2 or its complement.
- 4. (Currently Amended) An isolated nucleic acid comprising a nucleic acid sequence of which is SEQ ID NO: 1 or its complement.
- 5. (Currently Amended) The nucleic acid of claim 3, wherein said nucleic acid encodes <u>a</u> polypeptide comprising amino acids 23-170 of SEQ ID NO: 2.
- 6. (Previously Amended) An isolated nucleic acid encoding a polypeptide, wherein said polypeptide has a single conservative amino acid substitution relative to the polypeptide of SEQ ID NO: 2, or its complement.
- 7. (Previously Amended) An isolated nucleic acid that hybridizes under stringent conditions with the nucleic acid of claim 1, wherein said stringent conditions comprise hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C.
- 8. (Previously Amended) An isolated nucleic acid that hybridizes under stringent conditions with the nucleic acid of SEQ ID NO: 1, wherein said stringent conditions comprise hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C.
- 9.(Canceled).
- 10. (Original) A vector comprising the nucleic acid of claim 1.
- 11. (Currently Amended) An isolated cell comprising the vector of claim 10.
- 12. (Currently Amended) The <u>isolated</u> cell of claim 11 wherein said cell is a <del>prokaryotic or</del> eukaryotic cell.
- 13. (Currently Amended) A composition comprising the nucleic acid of claim 1 and a pharmaceutically acceptable carrier.
- 14. (Currently Amended). A process for producing a the polypeptide of SEQ ID NO: 2, said process comprising:

Appl. No. 09/998,966 Amdt. dated March 1, 2004 Reply to Final Office action of October 30, 2003

- a) providing the <u>isolated</u> cell of claim 11, <u>wherein said isolated cell comprises a vector comprising an isolated nucleic acid comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 2;</u>
  - b) culturing said cell under conditions sufficient to express said polypeptide of SEQ ID NO: 2; and
  - c) recovering said polypeptide of SEQ ID NO: 2,

thereby producing said polypeptide of SEQ ID NO: 2.

- 15. (Currently Amended) The process of claim 14, wherein said cell is a prokaryotic or eukaryotic cell.
- 16. (Canceled).
- 17. (Canceled).
- 18. (New). The isolated cell of claim 11, wherein said cell is a prokaryotic cell.
- 19. (New) The process of claim 14, wherein said cell is a prokaryotic cell.